Get started
Heron Therapeutics, Inc.Heron Therapeutics, Inc.Heron Therapeutics, Inc.

Heron Therapeutics, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

HRTX trade ideas

HRTX - Biotech long play Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI. Investment Snapshot (As of May 31, 2024): Shares in Circulation: 116.291M Short Float: 26.03% Recent Activity: Blockbuy Active Stake Heron Therapeutics Submits ZYNRELEF® Supplement to FDA Key Technical Levels: Breakout Zone: $3.70 - $4.00. Note: A slight pullback to the $3.50 area is possible before moving higher. Resistance Points: $4.00 $4.50 Surpassing these levels could signal a positive trend. Consider taking profits at these stages to realize gains. Trading Strategy: Take Profit (TP): Target $4.50 or even $5.50 to capitalize on the anticipated price gap closure. Stop Loss (SL): Set at under $3.15 to mitigate potential losses. Chart Analysis: Please refer to the attached chart for detailed analysis of price trends and movements. Trading Advisory: Exercise caution and consider market conditions and your own risk tolerance when trading. It's advisable to conduct comprehensive research or consult with a financial advisor before engaging in trading activities. Disclaimer: This content is for informational purposes only and should not be considered financial advice.
NASDAQ:HRTXLong
by meitshels_smell_trades
HRTX a biotech penny stock with 70% in two months LONGHRTX has been suggested by various trading websites as a potentially explosive penny biotech stock for 2024. It has experienced excellent price actions since an earnings beat in November. It beat the estimates; that is to say it burned about half as much cash as the analysts estimated the it would. Today it pumped 11%. Relevant articles can be found compiled on the Yahoo Finance page linked here. The chart is 120 minutes. A alpha trend indicator is shown and the supertrend since the November earnings is upward. An AI Lorentzian indicator is added with a 2000 candle lookback to generate buy and sell signals. It calculated a 59% win on 83 trades over those 2000 candles two hours each; this amounts to about 2000 x 2 / 6 hrs per session or more than 600 trading days = 2 1/2 years. Also supporting an entry at this time is the faster (45 min) RSI line rising over the 50 level while the slower ( 240 minutes in red) RSI line has been over the 50 level since those earnings. The ADX indicator had a DI- and DI + flip with a mini pullback to close out last week's trading ( profit taking). The volatility indicator also showed that dip with selling volatility greater than buying which has now flipped. Given that price has went 5X in 2 months , there is a possibility HRTX is overbought. Analysts seem to think otherwise. I will take a stock position here and anticipate holding the position into the next earnings. For trade management I will take partials of 5 % each at the high of day for ten days going into earnings and hold the remaining 50% through the earnings. In the meanwhile I will review the trade if the machine-learning alo indicator generates either a buy or sell signal. For those lacking the risk tolerance for money-losing biotechnology penny stocks with high potential but are aware that biotechnology is expected to be "outperforming" in 2024, XBI and LABU are ETFs with risk-mitigation in the form of a diverse portfolio from the sector.
NASDAQ:HRTXLong
by AwesomeAvani
Potential rocket on 50-100%Heron Therapeutics, Inc - a biotech company whose main products are drugs for nausea and vomiting caused by chemotherapy (CINV), as well as painkillers. Capitalization of $1.2 billion. Located in San Diego, USA. In May of this year, the company received FDA approval for its "breakthrough" pain medication ZYNRELEF, which will change in surgery. ZYNRELEF is the first and only dual-acting local anesthetic with extended use (DALA ™ ), providing 72 hours of postoperative anesthesia with a single needle-free application. It has been clinically proven to cope better with pain than a standard bupivacaine HCl solution for 72 hours, and significantly reduces the use of opioids after surgery. The FDA approved the use of the drug only during operations on thumb bursitis, open inguinal hernia and knee arthroplasty, which significantly reduced its commercial potential and could not bring $HRTX significant revenue growth. Recently it became known that the FDA agreed to re-examine the original application for ZYNRELEF. If the drug is approved for a wide range of its applications, the company will be able to realize its commercial potential. The company also submitted an application for ZYNRELEF approval to the Ministry of Health of Canada, where approval will take up to 300 days. As of January 1, 2021, ZYNRELEF is approved in 31 European countries, including the countries of the European Union and the European Economic Area, as well as the United Kingdom. A reversal pattern is formed on the chart for the higher TF through the double bottom. The first touch of $10 support was in mid-March, then a touch in August with a technical rebound of 30%, then the price returned to $10 with the formation of a $9-10 trade. It is important to overcome the resistance of $ 13, then we can talk about breaking the trend. Can go with the current, dobora position blocks $8.5-10/$5.5-6.5. Now a lot of biotech has come to strong support levels and look ready 🚀 Wall Street analysts unanimously predict growth of $HRTX, minimum targets of $23-24. The first goal is the maximum accumulation level: $17 (+50%) The second goal is the annual maximum level: $24 (+100%) NOT IRR.
NASDAQ:HRTXLong
by Trader_Ivankov